The offering is a routine capital raise for a pre-revenue biotech with positive Phase 3 data. Monitor the timing of the NDA submission and any updates on the XR tablet Phase 3 trial (CHAPTER-3). The modest dilution is offset by extended cash runway, but no near-term catalyst from this filing alone.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 11 $29.95entry
- T+1 · 6mo ago 0.00%α +0.14% · $29.95
- T+5 · 6mo ago −3.81%α −3.72% · $28.81
- T+20 · 5mo ago +5.51%α +5.81% · $31.60
- T+60 · 3mo ago +11.59%α +7.19% · $33.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris filed a prospectus supplement for an underwritten public offering of 3,874,664 ordinary shares at $29.68 per share, with an option for an additional 581,199 shares. The offering is expected to raise approximately $107.5 million in net proceeds (or $123.7 million if the option is fully exercised), which will be used to fund late-stage clinical programs, US commercialization efforts, and working capital. The company reported $247 million in cash as of March 31, 2026, and the offering extends its runway into the first half of 2028.
Key Facts
- Offering 3,874,664 shares at $29.68 per share, total gross proceeds of $115 million
- Underwriters have a 30-day option to purchase up to an additional 581,199 shares
- Net proceeds estimated at $107.5 million ($123.7 million with option exercise)
- Proceeds to fund R&D for late-stage programs, US commercialization, and working capital
- Cash and cash equivalents of approximately $247 million as of March 31, 2026
- Immediate dilution of $23.51 per share for new investors based on December 31, 2025 book value
- Shares outstanding will increase from 65,210,590 to up to 69,666,453 (if option exercised)
- Company plans to submit NDA for deucrictibant IR capsules in H1 2026
Financial Impact
Dilution of ~5.9% to existing shareholders; net proceeds of $107.5M extend runway into H1 2028
Risk Factors
- Immediate dilution of $23.51 per share for new investors
- No revenue, pre-commercial stage; reliance on regulatory approval
- Potential further dilution if additional capital is needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-214985 |
| Document: d36127dexfilingfees.htm | 0001193125-26-214985 |
| Document: 0001193125-26-214985-index-headers.html | 0001193125-26-214985 |
| Document: 0001193125-26-214985-index.html | 0001193125-26-214985 |
| Document: 0001193125-26-214985.txt | 0001193125-26-214985 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers